MediciNova (MNOV) tacks on an additional 12.4% gain from yesterday's big move, after the company...


MediciNova (MNOV) tacks on an additional 12.4% gain from yesterday's big move, after the company said its MN-166 drug treatment for methamphetamine dependence has been granted fast-track status by the FDA.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs